126
|
Cottin V, Bergot E, Bourdin A, Cadranel J, Camus P, Crestani B, Dalphin JC, Dromer C, Israel-Biet D, Jouneau S, Kessler R, Marchand-Adam G, Marquette C, Prévot G, Reynaud-Gaubert M, Valeyre D, Wallaert B, Bouquillon B, Cordier JF. Seconde enquête de pratique sur la prise en charge de la fibrose pulmonaire idiopathique en France. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2014.10.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
127
|
Tabeze L, Borie R, Cottin V, Nathan N, Nunes H, Naccache J, Valeyre D, Cadranel J, Amselem S, Tazi A, Israel-Biet D, Marchand-Adam S, Prevot G, Reynaud Gaubert M, Clement A, Cordier J, Crestani B, Kannengiesser C. Prévalence de mutations identifiées dans les suspicions de formes génétiques de fibroses. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2014.11.054] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
128
|
Beau-Faller M, Texier M, Blons H, Richard N, Escande F, Bièche I, Lizard S, De Fraipont F, Morin F, Zalcman G, Pignon J, Cadranel J. Ermetic-2 Project : Impact of Systematic Egfr and Kras Mutation Evaluation By Alternative Testing Methods on Progression-Free (Pfs) and Overall Survival (Os) in Patients with Advanced Non–Small-Cell Lung Cancer (Nsclc) Treated By Erlotinib (E) in the Ifct Ermetic Cohort. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.88] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
129
|
Jeannot V, Busser B, Brambilla E, Wislez M, Robin B, Cadranel J, Coll JL, Hurbin A. The PI3K/AKT pathway promotes gefitinib resistance in wild-type EGFR lung adenocarcinoma by a deacetylase-dependent mechanism. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2014.04.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
130
|
Vieira T, Antoine M, Poulot V, Schlick L, Rabbe N, Rodenas A, Duruisseaux M, Fallet V, Lacave R, Cadranel J, Wislez M. Profil anatomo-clinique et moléculaire des carcinomes bronchopulmonaires primitifs de type sarcomatoïde. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2014.04.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
131
|
Ferrand H, Crockett F, Naccache JM, Rioux C, Mayaud C, Yazdanpanah Y, Cadranel J. [Pulmonary manifestations in HIV-infected patients: a diagnostic approach]. Rev Mal Respir 2014; 31:903-15. [PMID: 25496788 DOI: 10.1016/j.rmr.2014.04.106] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2013] [Accepted: 04/25/2014] [Indexed: 01/12/2023]
Abstract
The spectrum of pulmonary diseases that can affect human immunodeficiency virus (HIV)-infected patients is wide and includes both HIV and non-HIV-related conditions. Opportunistic infections and neoplasms remain a major concern even in the current era of combination antiretroviral therapy. Although these diseases have characteristic clinical and radiological features, there can be considerable variation in these depending on the patient's CD4 lymphocyte count. The patient's history, physical examination, CD4 count and chest radiograph features must be considered in establishing an appropriate diagnostic algorithm. In this article, we propose different diagnostic approaches HIV infected to patients with respiratory symptoms depending on their clinico-radiological pattern.
Collapse
|
132
|
Gounant V, Khalil A, Créquit P, Lavole A, Ruppert AM, Antoine M, Milleron B, Wislez M, Carette MF, Assouad J, Cadranel J. 2014 update on non-small cell lung cancer (excluding diagnosis). Diagn Interv Imaging 2014; 95:721-5. [PMID: 25027710 DOI: 10.1016/j.diii.2014.05.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Lung cancer (LC) is a major public health issue because of its frequency, but especially because of the severity of this disease. The epidemiology has changed with an increased incidence in non-smokers and women. The ATS/ERS/IASLC classification of adenocarcinomas was modified in 2011, and they are now the most frequent histological subtype. More than half the cases of LC are diagnosed at the metastatic stage. Biopsies must provide tissue samples that are quantitatively large enough and of a good enough quality for diagnosis and to search for biomarkers. When the cancer seems to be localized, precise staging must be obtained. Treatment is based on the TNM classification. In localized stages, lobectomy associated with lymph node dissection is the standard therapy. Intraoperative chemotherapy improves survival in case of lymph node infiltration. Stereotactic radiation therapy and radiofrequency can be considered as specific cases. In cases with local progression, treatment is more controversial. In the presence of metastases, the goal is not a cure, but improving survival and quality of life. Numerous advances have been made with personalized treatment, (in particular in relation to the histological type and oncogenic addiction in tumors, access to new drugs, and improved management). Clinical research in thoracic cancer is very active. The fight against tobacco should remain a priority.
Collapse
|
133
|
Jeannot V, Busser B, Brambilla E, Wislez M, Robin B, Cadranel J, Coll J, Hurbin A. 495: AKT and gefitinib resistance in mutant KRAS non-small cell lung cancers through mechanisms dependent of acetylation. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50440-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
134
|
Comarmond C, Crestani B, Tazi A, Hervier B, Adam Marchand S, Nunes H, Cohen-Aubart F, Wislez M, Cadranel J, Housset B, Lloret-Linares C, Sève P, Pagnoux C, Abad S, Camuset J, Bienvenu B, Duruisseaux M, Hachulla E, Arlet JB, Hamidou M, Mahr A, Resche-Rigon M, Brun AL, Grenier P, Cacoub P, Saadoun D. FRI0460 Pulmonary Fibrosis in Anca-Associated Vasculitis: Clinical Characteristics and Long-Term Followup of 49 Patients. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.4159] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
135
|
Cadranel J. Aspergilloses pulmonaires chroniques. J Mycol Med 2014. [DOI: 10.1016/j.mycmed.2014.01.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
136
|
Mayaud C, Cadranel J. Le poumon du VIH de 1982 à 2013. Rev Mal Respir 2014; 31:119-32. [DOI: 10.1016/j.rmr.2013.09.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2012] [Accepted: 07/11/2013] [Indexed: 10/26/2022]
|
137
|
Cottin V, Crestani B, Valeyre D, Wallaert B, Cadranel J, Dalphin JC, Delaval P, Israel-Biet D, Kessler R, Reynaud-Gaubert M, Cordier JF, Aguilaniu B, Bouquillon B, Carré P, Danel C, Faivre JB, Ferretti G, Just N, Kouzan S, Lebargy F, Marchand Adam S, Philippe B, Prévot G, Stach B, Thivolet-Béjui F. Erratum à « Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique » [Rev. Mal. Respir. 30 (10) 879–902]. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2014.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
138
|
Barlesi F, Blons H, Beau-Faller M, Rouquette I, Ouafik L, Mosser J, Merlio J, Bringuier P, Jonveaux P, Le Marechal C, Denis M, Penault-Llorca F, Debieuvre D, Soria J, Cadranel J, Mazieres J, Missy P, Morin F, Nowak F, Zalcman G. Biomarqueurs France : résultats de l’analyse en routine de EGFR, HER2, KRAS, BRAF, PI3K, et ALK sur 10 000 patients (pts) atteints de cancer bronchique non à petites cellules (CBNPC). Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2013.10.041] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
139
|
Lavolé A, Lejeune C, Epaud C, Rosencher L, Ruppert AM, Gounant V, Créquit P, Rousseau-Bussac G, Wislez M, Cadranel J. Délai de prise en charge du cancer du poumon (CP) en hôpital de jour d’un centre expert en oncologie thoracique. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2013.10.478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
140
|
Beau-Faller M, Prim N, Ruppert AM, Nanni-Metéllus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet JL, Rouquette I, de Crémoux P, Solassol J, de Fraipont F, Bièche I, Cayre A, Favre-Guillevin E, Tomasini P, Wislez M, Besse B, Legrain M, Voegeli AC, Baudrin L, Morin F, Zalcman G, Quoix E, Blons H, Cadranel J. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol 2013; 25:126-31. [PMID: 24285021 DOI: 10.1093/annonc/mdt418] [Citation(s) in RCA: 233] [Impact Index Per Article: 21.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND There is scarce data available about epidermal growth factor receptor (EGFR) mutations other than common exon 19 deletions and exon 21 (L858R) mutations. PATIENTS AND METHODS EGFR exon 18 and/or exon 20 mutations were collected from 10 117 non-small-cell lung cancer (NSCLC) samples analysed at 15 French National Cancer Institute (INCa)-platforms of the ERMETIC-IFCT network. RESULTS Between 2008 and 2011, 1047 (10%) samples were EGFR-mutated, 102 (10%) with rare mutations: 41 (4%) in exon 18, 49 (5%) in exon 20, and 12 (1%) with other EGFR mutations. Exon 20 mutations were related to never-smoker status, when compared with exon 18 mutations (P < 0.001). Median overall survival (OS) of metastatic disease was 21 months [95% confidence interval (CI) 12-24], worse in smokers than in non-smoker patients with exon 20 mutations (12 versus 21 months; hazard ratio [HR] for death 0.27, 95% CI 0.08-0.87, P = 0.03). Under EGFR-tyrosine kinase inhibitors (TKIs), median OS was 14 months (95% CI 6-21); disease control rate was better for complex mutations (6 of 7, 86%) than for single mutations (16 of 40, 40%) (P = 0.03). CONCLUSIONS Rare EGFR-mutated NSCLCs are heterogeneous, with resistance of distal exon 20 insertions and better sensitivity of exon 18 or complex mutations to EGFR-TKIs, probably requiring individual assessment.
Collapse
|
141
|
Lavolé A, Toper C, Belmont L, Ruppert AM, Wislez M, Cadranel J. [Lung cancer and HIV infection]. Rev Mal Respir 2013; 31:133-41. [PMID: 24602680 DOI: 10.1016/j.rmr.2013.07.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2012] [Accepted: 07/11/2013] [Indexed: 01/18/2023]
Abstract
AIDS was the cause of the majority of deaths from HIV infection before 1996 but since the introduction of antiretroviral therapies the causes of mortality have changed considerably. In 2010, 75 % of deaths were due to diseases other than AIDS, the majority being cancers. Lung cancer is the most common in terms of both incidence and mortality. It shows specific features when compared to the general population: there is an excess risk due to heavy smoking but also probably due to immunosuppression. The age of onset is younger and the prognosis worse than in the general population. Management is difficult, partly due to the aggressive nature of the tumor and partly to co-morbidities and potential interactions between anticancer and antiretroviral therapies. A phase II therapeutic trial (IFCT-CHIVA 1001) is under way nationally.
Collapse
|
142
|
Ruppert AM, Amrioui F, Gounant V, Wislez M, Bouvier F, Cadranel J. Le sevrage tabagique en oncologie thoracique. Rev Mal Respir 2013; 30:696-705. [DOI: 10.1016/j.rmr.2013.02.017] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2012] [Accepted: 02/23/2013] [Indexed: 11/29/2022]
|
143
|
Giroux Leprieur E, Antoine M, Vieira T, Duruisseaux M, Poulot V, Rabbe N, Belmont L, Gounant V, Lavolé A, Milleron B, Lacave R, Cadranel J, Wislez M. Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy. Lung Cancer 2013; 79:167-72. [DOI: 10.1016/j.lungcan.2012.10.010] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2012] [Revised: 09/18/2012] [Accepted: 10/16/2012] [Indexed: 11/16/2022]
|
144
|
Gounant V, Ruppert AM, Fenane H, Giol M, Karsenti A, Cadranel J, Assouad J. Épidémiologie des pneumothorax : expérience d’un centre spécialisé « SOS pneumothorax ». Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
145
|
Duruisseaux M, Antoine M, Rodenas A, Rabbe N, Schlick L, Vieira T, Belmont L, Cadranel J, Wislez M. Profil des adénocarcinomes (ADC) lépidiques non-mucineux (NM) et des variants mucineux (M) selon l’expression de MUC1, MUC2, MUC5AC et MUC6. Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
146
|
Taillé C, Grootenboer-Mignot S, Nunes H, Carton Z, Cottin V, Israël-Biet D, Cadranel J, Wallaert B, Valeyre D, Chollet-Martin S, Crestani B. Prévalence et pronostic des anticorps antipériplakine au cours de la fibrose pulmonaire idiopathique. Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.092] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
147
|
Ruppert AM, Gounant V, Gasparini P, Fenane H, Bouvier P, Cadranel J, Assouad J. Pneumothorax spontané primitif : prévalence de la consommation de tabac et de cannabis et échec du sevrage. Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
148
|
Borie R, Crestani B, Dieudé P, Nunes H, Allanore Y, Kannengiesser C, Airo P, Matucci-Cerinic M, Wallaert B, Israel-Biet D, Cadranel J, Cottin V, Valeyre D, Grandchamp B. Le polymorphisme commun de MUC5B est associé à la fibrose pulmonaire idiopathique mais pas à l’atteinte interstitielle de la sclérodermie. Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
149
|
Duchemann B, Annesi-Maesano I, Jacobe De Naurois C, Liote H, Neuville M, Naccache JM, Boris R, Mekinian A, Mathieu M, Crestani B, Cadranel J, Fain O, Valeyre D, Nunes H. Prévalence et incidence des pneumopathies interstitielles diffuses chroniques (PIDC) en Seine-Saint-Denis (SSD) : analyse à 8 mois. Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
150
|
Vieira T, Girard N, Ung M, Monnet I, Bonnette P, Cazes A, Duruisseaux M, Lavole A, Antoine M, Mazieres J, Cadranel J, Wilsez M. Efficacité d’une première ligne de chimiothérapie (CT) chez 97 patients atteints de carcinomes sarcomatoïdes pulmonaires (CS). Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|